Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
US11324834B2 · kind B2 · utility
0Cited by
10References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2018 |
| Grant date | May 10, 2022 |
| Priority date | — |
| Expiry date | Jun 12, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.